NCT00936897View on ClinicalTrials.gov

A Study to Evaluate the Safety and Efficacy of Denosumab and Ibandronate in Postmenopausal Women Sub-Optimally Treated With Daily or Weekly Bisphosphonates

PHASE3CompletedINTERVENTIONAL
Enrollment

833

Participants

Timeline

Start Date

July 31, 2009

Primary Completion Date

November 30, 2011

Study Completion Date

January 31, 2012

Conditions
Postmenopausal Osteoporosis
Interventions
DRUG

Ibandronate

Ibandronate 150mg PO QM (tablet)

DRUG

Denosumab

denosumab 60mg SC Q6M (pre-filled syringe)

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY

NCT00936897 - A Study to Evaluate the Safety and Efficacy of Denosumab and Ibandronate in Postmenopausal Women Sub-Optimally Treated With Daily or Weekly Bisphosphonates | Biotech Hunter | Biotech Hunter